Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management

Mohler, James L.

doi:10.6004/jnccn.2016.0186

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRPC inevitably develops despite this initial response to ADT. 2 CRPC still has a poor prognosis although there are some therapeutic options including taxane chemotherapy, androgen receptor axis-targeted therapy, and targeted alpha therapy.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

et al. 2021

View full text Add to dashboard Cite

Abbreviations & Acronyms ADT = androgen deprivation therapy ARs = androgen receptors CRPC = castration-resistant prostate cancer DC = dendritic cell e-MDSC = early-stage myeloidderived suppressor cells GnRH = gonadotropin-releasing hormone MDSCs = myeloid-derived suppressor cells M-MDSC = monocytic myeloidderived suppressor cells MRI = magnetic resonance image PBMCs = peripheral blood cells PC = prostate cancer PMN-MDSC = polymorphonuclear myeloid-derived suppressor cells PR = partial response PSA = prostate-specific antigen STAT = signal transducer and activator of transcription TUC = transurethral electrocoagulation

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

The role of ketoconazole in current prostate cancer care

Patel

Liaw

2018

Nat Rev Urol

View full text Add to dashboard Cite

Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor that has been used, off-label, as a second-line therapy for castration-resistant prostate cancer (CRPC). The drug has shown clinical efficacy without survival benefit. Despite not improving survival, ketoconazole has beneficial characteristics, such as its low cost, a relatively favourable toxicity profile compared with chemotherapy, and its efficacy both before and after chemotherapy. The approval of several new, highly effective treatments, including abiraterone acetate, enzalutamide, and apalutamide, warrants re-evaluation of the role of ketoconazole and other classic agents in achieving the optimal timing and sequencing of available agents to prolong survival and maintain patients' quality of life. In the current CRPC treatment landscape, we believe that ketoconazole can be considered in patients with nonmetastatic CRPC and in those with metastatic CRPC who do not respond to, tolerate, or have access to chemotherapy and other standard therapeutic options.

show abstract

PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

et al. 2019

View full text Add to dashboard Cite

Background Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice. Methods This was a cross-sectional, multicentre study. Male chemo-naïve adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables). Results A total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 ± 16.3 and 108.7 ± 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone ≥3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone ≥3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively). Conclusion Our data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naïve CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naïve mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT. Trial registration Not applicable since it is not an interventional study.

show abstract

Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management

Cited by 5 publications

References 18 publications

Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

The role of ketoconazole in current prostate cancer care

PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

Contact Info

Product

Resources

About